Welcome to our dedicated page for TriSalus Life Sciences SEC filings (Ticker: TLSI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TriSalus Life Sciences, Inc. (Nasdaq: TLSI) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. TriSalus identifies itself in these filings as an emerging growth company and an oncology-focused medical technology business built around its Pressure-Enabled Drug Delivery (PEDD) platform and investigational immunotherapy, nelitolimod.
Through Forms 8-K, TriSalus reports material events such as quarterly financial results, business updates, changes in directors, compensation decisions and capital structure actions. Recent 8-K filings describe press releases announcing results for quarters ended June 30 and September 30, 2025, along with revenue performance driven by sales of the TriNav system. Other 8-Ks detail an exchange offer and consent solicitation related to Series A Convertible Preferred Stock, amendments to the certificate of designations, and subsequent conversion of preferred shares into common stock.
These filings also document governance and compensation matters, including director resignations and adjustments to executive base salary and performance-based stock option grants that vest upon achieving specified revenue thresholds. Together, they provide insight into how TriSalus manages its capital structure, aligns management incentives and responds to financing needs while advancing its PEDD-based devices and clinical-stage immunotherapy.
On Stock Titan, SEC documents for TLSI are updated as they are made available through EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, operating results, capital structure changes and governance items, and make it easier to interpret the implications of each report. This allows users to quickly understand what TriSalus is disclosing about its operations, financial condition and strategic decisions without reading every page in detail.
Form 4 filing overview: On 06/12/2025, TriSalus Life Sciences, Inc. (TLSI) director Kerry R. Hicks was granted a non-qualified stock option for 15,000 shares of common stock at an exercise price of $5.50 per share. The option expires on 06/11/2035 and will vest in full on the earlier of 06/12/2026 or the company’s next annual shareholder meeting, subject to continued board service.
Following the grant, Mr. Hicks now beneficially owns 89,222 derivative securities (principally stock options). The filing indicates direct ownership; no indirect holdings were reported. No purchases or sales of common stock occurred, and the filing does not disclose any change to Mr. Hicks’ non-derivative share count.
The transaction was coded “A” (acquisition), routine for director compensation, and was not executed under a Rule 10b5-1 plan. Because the filing relates only to an option grant—without an accompanying open-market trade—its immediate market impact is typically limited. Nevertheless, investors may view the award as modest alignment of director incentives with shareholder interests through long-dated equity compensation.
TriSalus Life Sciences, Inc. (TLSI) filed a Form 4 reporting a routine equity award to director Sean Murphy. On 06/12/2025 Mr. Murphy was granted 15,000 non-qualified stock options with an exercise price of $5.50 per share. The award will fully vest on the earlier of one year from grant or the company’s next annual shareholder meeting, contingent on his continued service. The options expire on 06/11/2035. After the grant, the director beneficially owns 554,681 derivative securities (options) in aggregate. No shares of common stock were bought or sold; this filing solely reflects the incentive grant and therefore does not immediately affect the public float or insider ownership percentage.
TriSalus Life Sciences, Inc. (TLSI) – Form 4 insider filing: Director William Valle reported the grant of stock options covering 15,000 common shares on 12-Jun-2025 at an exercise price of $5.50 per share. The option fully vests on the earlier of 12-Jun-2026 or the next annual shareholder meeting, conditional on continued board service. Following the award, Valle’s total beneficial holding of derivative securities (options) rose to 56,250, all held directly.
No open-market purchases, sales, or changes in non-derivative common stock were reported. The transaction is a routine director compensation item and does not alter the company’s share count or cash position.
Form 4 Overview – TriSalus Life Sciences, Inc. (TLSI)
Director Mats Wahlstrom reported an acquisition of derivative securities on 12 June 2025. The filing records a grant of 15,000 non-qualified stock options (‘Director Stock Option – right to buy’) with an exercise price of $5.50 per share. These options will fully vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the next annual shareholder meeting, contingent upon continued board service.
Following this grant, Mr. Wahlstrom now holds a total of 200,945 derivative securities (options) in a direct ownership capacity. No common shares were bought or sold, and no cash consideration exchanged hands at the time of the grant. The option’s expiration date is 11 June 2035, providing a 10-year exercise window once vested.
This transaction represents routine director compensation and does not alter the company’s outstanding share count or cash position. It signals continued alignment of the director’s incentives with shareholder returns but is not expected to have a material impact on TLSI’s near-term financials or market valuation.
TriSalus Life Sciences, Inc. (Nasdaq: TLSI) filed an 8-K to announce the launch of a dual exchange offer and consent solicitation aimed at retiring its outstanding Series A Convertible Preferred Stock. Holders who tender will receive a number of common shares equal to the sum of the preferred share’s Liquidation Preference plus all accrued dividends through August 10, 2027, divided by $4.00 per share. The company is offering up to 11,860,206 new common shares in total.
Concurrently, TriSalus seeks holder approval to amend the Certificate of Designations so that any preferred shares not exchanged can be mandatorily converted at a ratio that is 11.3 % less favorable than the voluntary exchange ratio. Investors representing approximately 55 % of outstanding preferred shares have already executed Tender and Support Agreements, effectively securing majority backing for both the exchange and the amendment, provided other conditions are met.
The offer began on June 23, 2025 and is scheduled to expire one minute after 11:59 p.m. EST on July 23, 2025, unless extended. Preferred holders may withdraw tenders any time before expiration. The transaction is being effected through a Form S-4 registration statement and Schedule TO filed the same day; investors are urged to review these filings for full terms and risk factors.
If completed, the exchange would eliminate a cumulative dividend obligation, simplify the capital structure, and remove an overhang that could impede future financing. However, it will also dilute existing common shareholders by up to roughly 25 % of the current basic share count, subject to final participation levels.
TriSalus Life Sciences, Inc. (TLSI) has filed a Form S-4 registration statement connected with a planned business combination. The excerpt provided is an XBRL tag listing that identifies numerous financial instruments and contractual arrangements but does not include any numerical values, pro-forma financials, or narrative description of the transaction.
Key elements referenced in the tags include:
- Standby Equity Purchase Agreement (SEPA) – suggests an equity financing back-stop to raise capital post-combination.
- Secured loan facilities with multiple maturity dates (June 30 2025 and December 31 2025) and association with OrbiMed, indicating the presence of debt financing.
- Extensive warrant structures (public, private, working-capital, SPAC, OrbiMed) and contingent earn-out liabilities, highlighting potential future dilution and performance-linked payouts.
- Derivative liabilities linked to the SEPA and warrants, implying fair-value accounting requirements.
- Tags for fair-value hierarchy levels 1 and 2, measurement inputs (share price, volatility, risk-free rate), and subsequent events dated through 30 April 2025.
- Mentions of revision of prior-period errors, indicating restatement activity, and Tags for preferred stock, common stock, and paid-in capital balances.
The filing appears highly complex—with numerous financing instruments, derivative features, and revisions—yet the excerpt lacks the monetary amounts or the terms necessary to quantify dilution, leverage, or valuation impact. Investors will need the full S-4 narrative and financial tables (not included here) to evaluate the transaction’s economics, pro-forma ownership, and forward-looking risks.